- Home
- NTIP vs BNR Comparison
NTIP vs BNR Comparison
Compare NTIP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- BNR
- Stock Information
- Founded
- NTIP 1990
- BNR 2014
- Country
- NTIP United States
- BNR China
- Employees
- NTIP N/A
- BNR N/A
- Industry
- NTIP Multi-Sector Companies
- BNR Medical Specialities
- Sector
- NTIP Miscellaneous
- BNR Health Care
- Exchange
- NTIP Nasdaq
- BNR Nasdaq
- Market Cap
- NTIP 32.0M
- BNR 38.3M
- IPO Year
- NTIP 1998
- BNR 2020
- Fundamental
- Price
- NTIP $1.60
- BNR $8.43
- Analyst Decision
- NTIP
- BNR
- Analyst Count
- NTIP 0
- BNR 0
- Target Price
- NTIP N/A
- BNR N/A
- AVG Volume (30 Days)
- NTIP 65.6K
- BNR 38.7K
- Earning Date
- NTIP 10-23-2025
- BNR 09-08-2025
- Dividend Yield
- NTIP 6.25%
- BNR N/A
- EPS Growth
- NTIP N/A
- BNR N/A
- EPS
- NTIP N/A
- BNR N/A
- Revenue
- NTIP $150,000.00
- BNR $74,862,782.00
- Revenue This Year
- NTIP N/A
- BNR $136.32
- Revenue Next Year
- NTIP N/A
- BNR N/A
- P/E Ratio
- NTIP N/A
- BNR N/A
- Revenue Growth
- NTIP N/A
- BNR 5.20
- 52 Week Low
- NTIP $1.16
- BNR $2.18
- 52 Week High
- NTIP $1.90
- BNR $11.12
- Technical
- Relative Strength Index (RSI)
- NTIP 55.71
- BNR 52.42
- Support Level
- NTIP $1.56
- BNR $8.02
- Resistance Level
- NTIP $1.63
- BNR $9.55
- Average True Range (ATR)
- NTIP 0.08
- BNR 0.66
- MACD
- NTIP -0.01
- BNR -0.15
- Stochastic Oscillator
- NTIP 28.57
- BNR 33.65
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.